EE459 Early Intensification of Oral Semaglutide in the UK: A Cost-Effectiveness Analysis Versus Continuing Metformin and SGLT-2 Inhibitor Therapy

A number of people with type 2 diabetes experience clinical inertia, remaining in poor glycaemic control on oral antidiabetic medications such as metformin and sodium-glucose cotransporter-2 (SGLT-2) inhibitors rather than treatment-intensifying with a glucagon-like peptide-1 receptor agonist, despite an efficacious, orally administered option, oral semaglutide, being available. The present study evaluated the long-term cost-effectiveness of immediate oral semaglutide treatment versus continuing metformin plus SGLT-2 inhibitor therapy in the UK.